Lung cancer trial combines two treatments to outsmart resistance

NCT ID NCT04410796

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the combination can delay cancer growth or spread. About 571 participants will be enrolled, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: osimertinib, carboplatin, and pemetrexed
What this could lead to: If successful, this could provide a more effective treatment option for people with EGFR-mutant lung cancer whose cancer shows signs of resistance to osimertinib alone.
What could go wrong: This is a phase 2 trial, so results are not yet proven. Adding chemotherapy may increase side effects without improving outcomes, and the benefit may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Columbia University (Data Collection Only)
ACTIVE_NOT_RECRUITING

New York, New York, 10032, United States
Hackensack Meridian Health
RECRUITING

Hackensack, New Jersey, 07601, United States
John Hopkins Medical Center
RECRUITING

Baltimore, Maryland, 21287, United States
MD ANDERSON CANCER CENTER (Data Collection Only)
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital (Data Collection Only)
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All protocol activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Limited protocol activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited protocol activities)
RECRUITING

Harrison, New York, 10604, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
New York University
ACTIVE_NOT_RECRUITING

New York, New York, 10010, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
UC Davis Cancer Center (Data Collection Only)
RECRUITING

Sacramento, California, 95817, United States
University of California San Francisco
ACTIVE_NOT_RECRUITING

San Francisco, California, 94143, United States
University of Washington (Data Collection Only)
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.